Markets · Global Equities · US

Roivant Sciences Ltd. ROIV

Exchange Nasdaq. Sector Pharma & biotech. Source: SEC companyfacts. Not a price feed.

• Revenue TTM 7.18M
• EBITDA TTM -1.28B
• Net debt -3.52B
• ND/EBITDA 2.74
• EBITDA/interest -31.3
• ROE -0.19
• Implied band B

All countries